XPONANCE, INC. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 242 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.

Quarter-by-quarter ownership
XPONANCE, INC. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q2 2024$912,903
+133.2%
13,329
+135.6%
0.01%
+125.0%
Q1 2024$391,534
-3.7%
5,658
-0.3%
0.00%
-20.0%
Q4 2023$406,515
+41.6%
5,676
+3.0%
0.01%
+25.0%
Q3 2023$287,172
-17.3%
5,513
+0.6%
0.00%
-20.0%
Q2 2023$347,120
+13.4%
5,482
-3.0%
0.01%
+25.0%
Q1 2023$306,164
+2.9%
5,654
+0.6%
0.00%
-20.0%
Q4 2022$297,570
+14.4%
5,623
+0.4%
0.01%0.0%
Q3 2022$260,000
-7.8%
5,601
+13.5%
0.01%
-16.7%
Q2 2022$282,000
+20.0%
4,935
+28.7%
0.01%
+50.0%
Q1 2022$235,0003,8340.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q1 2022
NameSharesValueWeighting ↓
DCF Advisers, LLC 375,000$15,308,0005.42%
SILVERARC CAPITAL MANAGEMENT, LLC 113,258$4,623,0002.06%
Tri Locum Partners LP 150,783$6,155,0002.02%
COOPER/HAIMS ADVISORS, LLC 61,116$2,495,0001.64%
Vantage Consulting Group Inc 226,670$9,252,0001.61%
Nicholas Investment Partners, LP 598,261$24,421,0001.53%
Bellevue Group AG 3,609,919$147,357,0001.44%
GENERAL AMERICAN INVESTORS CO INC 350,804$14,320,0001.20%
Rhenman & Partners Asset Management AB 429,728$17,541,0001.19%
WASATCH ADVISORS LP 6,506,789$265,607,0001.08%
View complete list of INTRA CELLULAR THERAPIES INC shareholders